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Abstract  
 
Digital healthcare is a rapidly growing healthcare sector. Its importance has been recognised at both 
national and international level, with the World Health Organisation recently publishing its first global 
strategy for digital health. The use of digital technology within cystic fibrosis (CF) has also increased. 
CF is a chronic, life limiting condition, in which the treatment burden is high and treatment regimens 
are not static.  Digital technologies present an opportunity to support the lives of people with cystic 
fibrosis. We included 59 articles and protocols in this state of the art review, relating to 48 studies 
from 1999 until 2019. This provides a comprehensive overview of the expansion and evolution of the 
use of digital technology. Technology has been used with the aim of increasing accessibility to 
healthcare, earlier detection of pulmonary exacerbations and objective electronic adherence 
monitoring. It may also be used to promote adherence and self-management through education, 
treatment management Apps and social media.  
 
Introduction  
The digital technology sector is a rapidly growing industry, with recent estimates suggesting digital 
technology is worth £184 billion to the UK economy1 and $1,351 billion to the US economy.2 Digital 
technology has become more accessible than ever before, especially amongst children and young 
people, with the Royal College of Paediatrics and Child Health describing this generation as “digital 
natives”; growing up surrounded by digital information. It is also an emerging field within the 
healthcare sector. It is widely used amongst the general population to track and promote health 
changing behaviours with devices such as exercise trackers and fitness Apps. Disease specific 
interventions are also emerging.  In chronic obstructive pulmonary disease and asthma, there has 
been a move towards the use of digital technologies in the ongoing monitoring of disease and 
adherence promotion. Strategies include text messaging reminders and web-based and mobile 
applications to monitor and record symptoms.3,4 Its importance has been recognised by the World 
Health Organisation who recently published its first global strategy for digital health. This brought 
together evidence for digital health interventions currently in use and provided recommendations for 
future development.5  
 
Cystic fibrosis (CF) has also seen the application of digital technologies. CF is an autosomal recessive, 
multisystem disorder. In the UK there are around 10,000 people living with the condition, of which 
40% are under the age of 16.6 In the US around 34,000 people have CF,7 with the predicted life 
expectancy of 46 years for those born in 2017.8 CF is caused by abnormal functioning of the Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR), responsible for the transport of chloride and 
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regulating the movement of water and ions across epithelial surfaces. Based on the CF pig model, a 
defect in the CFTR protein may lead to abnormal mucous pH in the periciliary fluid and mucous stasis 
which is primarily responsible for the multisystem manifestations of CF.9,10 Specialist CF centres in 
conjunction with developments in treatments, improvements in antibiotic therapy, and better 
nutrition have improved outcomes for people with CF (pwCF).11 However, treatment regimens have 
become increasingly complex, with many patients prescribed daily airway clearance techniques 
(ACTs), exercise, inhaled and nebulised medications, pancreatic enzyme replacement (PERT) and 
dietary supplementation. Intravenous antibiotics are required for acute pulmonary infections, often 
more frequently as patients get older.  
 
Despite the complexity of CF therapies, much of the regimen can be completed in the patient’s home, 
allowing the integration of treatments into everyday routines, with regular monitoring from the CF 
team. However, treatments are tiring, time-consuming and burdensome; the average time spent on 
treatments for children in the UK is 137 minutes per day and 150 minutes in adults.12 In addition, the 
routines of adults and families of children with CF are not static; managing the condition is a dynamic 
process involving ongoing adaptation and readjustment.13 Managing treatments alongside daily life 
activities can therefore be challenging and restrictive. Digital technologies present an opportunity to 
support and improve the lives of pwCF. Indeed, pwCF and parents acknowledge the role of technology 
and there are a range of applications and platforms that have been designed by them for pwCF.  
The aim of this state of the art review is to provide comprehensive overview of the evolution of CF-
specific digital technologies and their effectiveness in the promotion of home monitoring, adherence 
or self-management in what is a rapidly changing area of medicine.  
Methods 
We conducted a systematic literature search of electronic databases and clinical trials registers from 
1/1/1999 to 14/02/2019. The protocol with full search strategies and inclusion criteria can be found 
at https://nottingham-repository.worktribe.com/output/2044553. Broad search criteria were used 
and full text, article abstracts, conference abstracts and trial protocols were considered for inclusion 
in order to increase sensitivity. Once duplicates were removed, a total of 1968 electronic search results 
were identified which were imported into Covidence14 and considered for inclusion. The search results 
were reviewed independently by two reviewers. We excluded 1,665 articles on title alone, leaving 303 
for full text screening, of which 51 articles met criteria for inclusion. Searches of clinical trials 
registered over the same time period identified 48 protocols, which following duplicate removal and 
screening, identified a further 8 studies. Once the final articles had been identified, data were 
independently extracted by both reviewers with results collated into MS Excel. We included 59 articles 
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and protocols (online table 1), relating to 48 studies. The general quality of the evidence was low; 
mainly consisting of small interventional and before after studies with only three full text randomised-
control trials (RCTs) and one systematic review. Figure 1 highlights the expansion of technology over 
the last twenty years. Although for the purposes of this review technology has been assessed for its 
role within either home monitoring, measuring adherence or self-management we recognise that in 
practice these are often inter-related concepts in relation to CF.  
 
Digital technology used for home monitoring  
Increasing accessibility to healthcare 
Centralisation of care means that many patients do not live in close proximity to their CF centre which 
potentially becomes a barrier to accessing healthcare. Therefore, digital technology has been explored 
as an option for remote delivery of care. Videoconferencing has been used for delivery of routine 
appointments, annual assessments and multidisciplinary team (MDT) discussions,15 with more recent 
studies also able to share imaging, educational slides, lung function and microbiology results. Although 
there was no significant difference in Forced Expiratory Volume in one second (FEV1) results reported 
with teleconferencing, one study described positive patient satisfaction and 63% felt it was as good as 
a face to face review.16 It has also been used more widely for delivering mental health services to pwCF 
online.17 These studies again were small interventional studies and larger RCTs are required to fully 
assess the impact on telehealthcare in remote delivery of care. An ongoing RCT, VIRTUAL-CF is using 
videoconferencing to the CF MDT with remote spirometry and oxygen saturation measurements for 
patients receiving intravenous antibiotics in the community. It is assessing whether this approach 
promotes health-related quality of life compared to standard community intravenous antibiotics 
care.18 
 
Home monitoring for early detection of pulmonary exacerbations 
Despite life expectancy improving, the majority of deaths in CF are still attributable to respiratory 
failure secondary to recurrent pulmonary exacerbations. Exacerbations also contribute to morbidity; 
worsening CF related diabetes and reducing health-related quality of life.19-21 Therefore, the use of 
digital technology has been evaluated to determine if it can lead to the earlier detection of 
exacerbations and subsequently reduce the rate of respiratory decline. One of the first uses of digital 
technology in this context was in the 1980s for home monitoring of respiratory symptoms and lung 
function.22 This, along with other earlier studies, used a combination of home spirometry, measuring 
physical parameters such as heart rate and oxygen saturations, blood glucose levels and respiratory 
symptom scoring with the results collated and sent via modem internet to the CF centre.23  In more 
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recent work, advances in technology have allowed streamlining of data transmission via Wifi or 
Bluetooth. A small non-randomised interventional study showed promising results in FEV1 status. Data 
collected from a Spirotel™ device (Medical International Research, Rome, Italy) were sent via email to 
the CF centre, with patients contacted if they met intervention criteria for an exacerbation based on 
FEV1 decline or oxygen saturations.24 A significantly smaller decline in annual FEV1 status was noted in 
the telehealth group over a 4.5 year period. However, these results were not subsequently supported 
by a large multi-centre RCT, the Early Intervention in Cystic Fibrosis Exacerbation (eICE) trial.25,26 Using 
twice weekly home spirometry (Viasys AM2 device, CareFusion, California, USA) and respiratory 
symptom scoring, patients were contacted by the CF team if a reduction in FEV1 greater than ten 
percent or an increase in respiratory symptoms was seen. The early intervention group had a shorter 
time to first exacerbation and more exacerbation treatments compared to the control group, however 
this was not associated with a slower FEV1 decline. The trial was stopped early for futility, as 
completing the trial was unlikely to show a difference in primary end point.27 
 
However, the eICE study highlights the issue of adherence. In a condition where treatment burden is 
already high, home monitoring adds an additional task for the patient to complete. Home monitoring 
studies have required data entry from once a month to three times a week.28,29 Adherence to 
telemonitoring in the eICE trial over 52 weeks was suboptimal; 50% of patients transmitted data once 
per week and only 19% twice per week as per the protocol, with an increased treatment burden score 
in the early intervention telemonitoring group.26 
 
 
Ongoing studies 
Current studies are assessing the use of smartphone applications for the earlier recognition of 
exacerbations through changes in respiratory symptoms. They hope to establish whether having 
monitoring which is less restrictive and more mobile would improve adherence and therefore 
outcomes.30,31 Unfortunately, preliminary data from  RCT (ACTRN12615000599572) suggests that the 
use of a smartphone for symptom reporting had no effect on the number of courses of antibiotics or 
days of antibiotic treatment, with full results awaited.32 
 
Digital technology for monitoring and promoting adherence and exercise 
 
 Home monitoring for supporting adherence 
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Adherence monitoring enables treatment guidance and allows clinicians to differentiate if changes in 
a patient’s condition are related to disease progression, attributable to poor adherence or a 
combination of the two. The impact of home monitoring on treatment adherence in adolescents and 
young adults has been explored in a before and after study using once weekly home monitoring and 
adherence monitoring using medication prescription refill data to calculate the medication possession 
ratio (MPR).33  In comparison to Lechtzin’s eICE study, adherence to weekly spirometry monitoring 
was 59% which may reflect the impact of parental supervision in this population group. Less frequent 
monitoring may have lessened the treatment burden to patients. There was a small associated overall 
increase in medication adherence; MPR was 60% in the year prior to study enrolment, and 65% during 
the 12 month study period (p=0.038). These authors found no change in the number of exacerbations 
or FEV1 decline between groups across the study period.33 
 
 
Digital technologies for adherence  
Self-monitoring also helps patients better understand and self-manage their condition.  However, self-
reporting of adherence is notoriously inaccurate and so alternative ways for adherence monitoring 
are being pursued. Prescription refill data and MPR is a valid and inexpensive way of monitoring 
adherence however, this is still prone to inaccuracies, as it is based on the assumption that all of the 
medications refilled are always taken.33 Hence digital technologies are being developed to more 
accurately record treatment adherence.34 
One small intervention study compared self versus digital electronic adherence recording of a high-
frequency chest wall compression vest (Vest System, Hill-Rom, Indiana, USA). Although the results 
showed a high variability in self-reporting, it supported the view that patients over-estimate treatment 
duration; by 127% in adults and 26% in parents of children wCF over a 2 week period. Overall average 
treatment adherence was 69%.35 
An established digital technology for adherence monitoring in CF is the data logging nebuliser device 
which combines routine nebuliser treatment with accurate adherence logging, via an electronic data 
capture facility. This gives an insight into how often and how long treatments are taking to build a 
picture of adherence. One such device is the I-NebTM (Respironics, Chichester, UK). It is an adaptive 
aerosol delivery system which adapts medication delivery to the patient’s breathing pattern, 
delivering only during inspiration.36,37 It also provides patients with visual and audio feedback whilst 
they undertake their treatments. Its data capturing facility allows trends to be identified. For example: 
although one study found adherence was maintained between 60-70% over one year, diurnal 
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variation was also noted; evening 70% vs 58% morning (p=0.012).36 This allows for more realistic joint 
goal setting and changes to treatments based on the results.35,36 However, this device is currently only 
available to a subset of patients prescribed PromixinTM (colistimethate sodium, Profile Therapeutics 
plc, West Sussex, UK) and although data logging devices may provide useful information to the CF 
team regarding adherence, some patients may find this level of monitoring intrusive.  
Insight OnlineTM (Respironics, Chichester, UK) has been developed to be used alongside the I-NebTM. 
It is a home monitoring telehealth interface, where patients upload data from the I-NebTM to a server. 
The data are then analysed and presented for patients and clinicians to view. Patients are encouraged 
to set treatment targets, against which they can self-monitor their progress. Data presented from a 
small intervention study had mixed results. This showed that for the patients who did engage it 
improved adherence, however over 50% of the participants failed to upload regularly.38 This result 
again raises the issue of increased treatment burden on patients, and that CF teams’ perceived benefit 
of technology may not be shared by all patients.   
Digital Technologies for exercise 
The video gaming industry is a continuously growing global industry accessed by 64% of the US 
population. Of those using game consoles, 76% played for at least 3 hours a week with the majority 
using it for significantly longer.39 Exercise is a key treatment in CF and, given the popularity of gaming 
technology, incorporating exercise through gaming has been explored as a strategy to help people to 
engage and self-monitor exercise. There have been small interventional studies using games consoles 
for promotion of home-based exercise.40 A RCT used the Nintendo Wii EA Sports Active 2 to deliver a 
six week training programme of 30-60 minute sessions, five days a week, monitored by a virtual 
personal trainer, with participants followed up for 12 months following the intervention.41,42 
Unfortunately this did not support the use of video gaming. Although both control and intervention 
groups showed a significant difference between physical parameters pre and post study, there was no 
difference between groups. In addition, although short term adherence was good, with 95% adherent 
at 6 weeks, this was not sustained and reduced to 35% using the game twice a week by 12 months, 
with 65% not using it at all.41 A potential reason is that if games are played frequently over an extended 
time period there is an element of monotony, similar to treatment regimens.   
Fitness trackers have been used within the general population for some time to promote exercise, 
with CF-specific trials focused mainly from 2017 onwards. A RCT by Bishay compared a fitness tracker 
with a personalised exercise prescription and social media platform to exercise prescription alone over 
a 12 month period.43 This study did not support the use of fitness trackers in CF with no significant 
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difference between the two groups in terms of exercise tolerance, pulmonary function or patient 
reported outcomes. 
There are other examples of social media and web-based platforms for exercise promotion. A small 
interventional pilot study used a closed Facebook group to promote a 30 day exercise challenge to 
increase daily exercise.44 Pactster in the UK (developed with the CF Trust) provided online exercise 
classes and included instructors who have CF.45 “CFYOGI” in the USA46 is an exercise web platform co-
founded by a pwCF and a parent of children with CF in partnership with Social Good Fund. It includes 
livestreamed and recorded fitness videos led by instructors with CF and has community features 
allowing patients to share progress and fitness goals while avoiding cross-infection risks. 
 
Ongoing studies  
The development of data-tracking nebulisers has led to the development of CFHealthHub 
observatory,47 a large scale data observatory which aims to recruit 6,000 pwCF over the period 2017-
2021 and collect observational data using patients’ data tracking nebulisers. In addition, it will be used 
as part of a large multicentre RCT (ISRCTN55504164)48 which will combine the use of data captured 
from data tracking nebulisers with behavioural change interventions available via a web portal, 
CFHealthHub. Data is available to be viewed by both clinicians and pwCF, with the primary outcome 
of the study being number of exacerbations. Secondly, a non-randomised cross over study 
(NCT02700243) is exploring the use of video games in improving adherence to ACTs using a positive 
expiratory pressure (PEP) device. Electronic versus self-reporting of adherence will be monitored over 
a 4 month period, following which a video game will be integrated into the PEP device operated by 
the patient performing their therapy correctly. Primary outcome is adherence to therapy, with change 
to pulmonary function a secondary outcome.49  
 
There are several ongoing studies in relation to exercise.50 ACTIVATE-CF,51 is using pedometers and 
daily web-based logging of exercise activities in addition to the standard care of 3 monthly counselling 
sessions to promote physical activity. Patients are encouraged to exercise 3 hours a week, with FEV1 
status being the primary outcome. Another RCT (NCT03672058) combines the use of FitbitTM exercise 
trackers (Fitbit, Inc. California, USA) with an online activity monitoring system (Fitabase) and 
personalised feedback on activity levels and progress, compared to the use of a Fitbit alone on steps 
per day and FEV1 status.52 Finally, project Fizzyo combines their use with ACT devices to assess activity 
levels, with chipped ACT devices used to capture daily adherence data.53 Data transmission appears 
more streamlined compared to other studies, with the results sent automatically once the ACT device 
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is synchronised with a tablet computer. In addition, computer games have been developed in 
conjunction with patients to be used at different intervals within the study to assess the impact of 
gaming on adherence.53 
 
 
Digital technology for education and self-management  
Self-management is key to successful management of chronic conditions such as CF. Self-management 
has been described as the process of helping patients and their families to choose, monitor and adjust 
their treatment requirements in relation to their condition and the effect it has on their lives.54  
 
Education  
Multiple digital technology platforms have been explored to promote self-management through 
education delivered as either self-guided sessions or mentor-supported individual or group web-based 
sessions. Whilst they may provide educational opportunities for participants, the self-management 
education and digital technologies themselves have had limited success, so far, in relation to patient 
outcomes. This is in keeping with a Cochrane review that suggested self-management education in CF 
could provide limited positive change for a small number of self-management behaviours.54  
 
Early education strategies explored education delivery via a CD-Rom, combining a computer game 
with education.55 Several platforms have since been developed. Web based education has increased 
in popularity, and the use of smartphones and Apps has been developed.56 CFfone provided access to 
the CFfone website via a smartphone, which contained educational materials and social support 
through inspirational stories and communication with peers in an online community.57 The BeInCharge 
study for parents of children with CF combined an education programme on dietary education, 
personalised calorie intake goals and behaviour techniques with a daily diet tracker App. Use of the 
App resulted in no significant increase in weight gain in the intervention group and indeed the App 
was less successful in achieving weight gain compared to the face-to face delivery used previously.58  
 
Individual education delivery for both children and adults guided by a mentor or physio has been 
explored. Patients in a small RCT, with two intervention treatment arms, used an online mentor-
guided self-efficacy programme with or without an App to monitor their symptoms and quality of life, 
compared to the control group.59 Results were limited by the small sample size although patients 
reported being confident in using digital technology. An increase in self-efficacy was seen across the 
intervention groups; however, this was similar in both groups with and without the use of the App. 
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Similarly, group sessions in CF have been limited to small interventional trials.60 Results of larger 
studies are required, one of which has recently been completed.61 This delivered 6 online modules 
relating to nutrition, medications and respiratory and liver disease. Patients also completed tasks and 
had access to videos of patients sharing their experiences. Preliminary data at 6 months show mixed 
results, with adherence data awaited. Significant improvements in body mass index and ADE vitamin 
levels were seen, however this did not translate to a reduction in lung function decline.61,62 
 
Ongoing studies using education  
Two large RCTs addressing this issue are due to be completed in 2019. Project UPLIFT provides group 
web-based education and intervention programme focusing on improving anxiety and depression in 
pwCF.63  Adherence is a secondary outcome. It focuses on education on depression and CF; coping 
strategies such as cognitive behavioural therapy and mindfulness; and relaxation techniques. An 
Australian project CyFiT, 64 encompasses several aspects of digital healthcare delivery. It combines the 
delivery of outpatient physiotherapy via videoconferencing, with additional multimedia and 
educational features. Participants are also given an activity tracker to record sleep and physiological 
parameters to guide exercise prescriptions and the telehealth sessions. The primary outcome is 
pulmonary function and the comparator is  standard physiotherapy.  Finally, a pilot study for a RCT 
(NCT03637504) plans to evaluate the feasibility of MedActionPlanTM (MedActionPlan, Peapack, USA); 
a web-based medication management App which uses education about treatment regimens to 
encourage self-management and adherence. Adherence is assessed using eTrack nebulisers and 
AdhereTechTM pill bottles (AdhereTech, New York, USA).65   
 
Digital technology for self-management of treatments  
Digital Apps are being used in a variety of contexts within CF including symptom monitoring, education 
and diet tracking. A newer area of interest is the development CF-specific Apps to help manage 
treatment regimens. “Genia” is a Swedish based treatment management App developed by a father 
and his daughter, who has CF,65 which allows pwCF to track their condition as well as providing the 
option to share information with care teams about symptoms, daily activities and medications, as well 
as sharing updates with family and friends.  
Ongoing Studies 
In the context of pancreatic insufficiency, smartphone Apps are under development which will be 
capable of calculating patient specific PERT requirements.66-68 MyCyFAPP is a multicentre, 
multidisciplinary development currently being tested which aims to allow patients to better self-
manage their PERT and nutrition. Importantly, parents and patients of various ages were involved in 
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the development phase as part of interviews and focus groups. The protocol describes a number of 
expected features of the App including education through games, food and symptom scoring records 
and a handbook containing nutritional information, in addition to calculating optimal PERT dosing. 
These data are also accessible to clinicians with alerts for suboptimal treatment, with the aim of 
promoting more focused and realistic goal setting at follow ups.68 
 
The use of social media for self-management in cystic fibrosis   
Social support is known to improve self-management and therefore the use of social media to provide 
social support has been explored, although CF-specific research is limited. A thematic analysis 
undertaken on a CF charity website message board found that online support groups seem to 
supplement professional support in relation to self-management and self-esteem.69 Social media has 
also been incorporated into projects such as CFfone (described previously).  No larger CF-specific 
studies were identified. 
 
Conclusion  
Digital technology is a growing industry. We have highlighted the expansion and evolution of its use 
in CF over the last 20 years for supporting home monitoring, adherence and self-management. Despite 
the large number of articles, most were small pilot and intervention studies without comparators and 
there were  very few full text RCTs. Although ongoing studies may yield some positive results, the 
majority so far have shown limited evidence to support the use of digital technology. An area of 
promise was electronic monitoring of adherence via data logging nebulisers to accurately capture 
adherence data. However, this does not address barriers to adherence. In addition, a potentially 
exciting area of development is the use of digital technology to assist in the self-management of 
medications, such as Apps providing patient-specific PERT dosing information. Future evaluation of 
the role of digital technology in CF will require well designed, adequately powered RCTs. Developers 
should be mindful that, in a condition where there is already a significant treatment burden, patients 
must find these technologies acceptable and sustainable. The benefits of digital technology must be 
carefully balanced against the investment of time needed to use them. Patient involvement in the 
design process is key. Furthermore, the benefits of treatment should be of benefit to the patient as 
well as the CF team.  
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